Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CY-503 in Chemotherapy-refractory Metastatic Colorectal Cancer
NCT00932724Phase 2Terminated
- Sponsor
- Cytavis BioPharma
- Start
- Jul 2009
- Primary completion
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing CY-503 with Placebo (2 arms). Primary endpoints: Progression-Free Survival and Tumor Assessment by CT/MRI. Started Jul 2009; status: terminated.
02
Drugs
aviscumine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00932724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00932724.